Chemours (CC) Receiving Somewhat Favorable News Coverage, Analysis Shows

Media coverage about Chemours (NYSE:CC) has been trending somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Chemours earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the specialty chemicals company an impact score of 46.0579948632228 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news articles that may have effected Accern’s analysis:

Shares of Chemours (NYSE CC) opened at 55.12 on Thursday. Chemours has a 52-week low of $14.41 and a 52-week high of $55.19. The company’s 50-day moving average is $51.91 and its 200-day moving average is $51.91. The stock has a market cap of $10.19 billion, a PE ratio of 36.07 and a beta of 3.59.

Chemours (NYSE:CC) last issued its quarterly earnings data on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.02. The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.49 billion. Chemours had a net margin of 10.14% and a return on equity of 140.38%. The company’s revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.27 EPS. Equities analysts anticipate that Chemours will post $3.51 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Thursday, August 17th were given a $0.03 dividend. The ex-dividend date was Tuesday, August 15th. This represents a $0.12 annualized dividend and a yield of 0.22%. Chemours’s dividend payout ratio (DPR) is 8.11%.

A number of equities research analysts recently commented on CC shares. Zacks Investment Research raised shares of Chemours from a “hold” rating to a “strong-buy” rating and set a $51.00 target price for the company in a research report on Friday, July 14th. BidaskClub cut shares of Chemours from a “buy” rating to a “hold” rating in a research report on Saturday, June 17th. Jefferies Group LLC reissued a “buy” rating and set a $48.00 target price on shares of Chemours in a research report on Friday, June 16th. Citigroup Inc. increased their target price on shares of Chemours from $45.00 to $59.00 and gave the company a “buy” rating in a research report on Friday, August 4th. Finally, J P Morgan Chase & Co increased their target price on shares of Chemours to $55.00 and gave the company an “overweight” rating in a research report on Friday, August 4th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $52.75.

ILLEGAL ACTIVITY WARNING: This story was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.com-unik.info/2017/10/12/chemours-cc-receiving-somewhat-favorable-news-coverage-analysis-shows.html.

In other Chemours news, insider E Bryan Snell sold 10,000 shares of the business’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $46.24, for a total value of $462,400.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Amy Trojanowski sold 2,500 shares of the business’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $46.03, for a total transaction of $115,075.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 57,837 shares of company stock valued at $2,885,523. 1.14% of the stock is owned by insiders.

About Chemours

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Insider Buying and Selling by Quarter for Chemours (NYSE:CC)

What are top analysts saying about Chemours Co? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chemours Co and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit